Issue: January, 2021 - JAMA Internal Medicine

$20.00

JAMA Internal Medicine is a monthly peer-reviewed medical journal published by the American Medical Association. It was established in 1908 as the Archives of Internal Medicine and obtained its current title in 2013.
Impact factor: 18.652 (2019)
Publisher: American Medical Association (United States)
ISSN: 2168-6106 (print); 2168-6114 (web)
ISO 4: JAMA Intern. Med
Frequency: Monthly
Discipline: Internal medicine

Additional information

Volume

181

Issue

1

Articles:

1. Watch Your Language! Misusage and Neologisms in Clinical Communication
2. No Bad Blood—Surviving Severe Anemia Without Transfusion
3. Assessment of Variation in State Regulation of Generic Drug and Interchangeable Biologic
Substitutions
4. Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With
COVID-19 Pneumonia: A Randomized Clinical Trial
5. Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or
Severe Pneumonia: A Randomized Clinical Trial
6. Association Between Early Treatment with Tocilizumab and Mortality Among Critically Ill
Patients With COVID-19
7. Assessment of Availability, Clinical Testing, and US Food and Drug Administration Review
of Biosimilar Biologic Products
8. Nutritional Analysis of Foods and Beverages Depicted in Top-Grossing US Movies, 1994-
2018
9. Effect of Recombinant Human Granulocyte Colony–Stimulating Factor for Patients with
Coronavirus Disease 2019 (COVID-19) and Lymphopenia: A Randomized Clinical Trial
10. Risk of Overcorrection in Rapid Intermittent Bolus vs Slow Continuous Infusion Therapies of
Hypertonic Saline for Patients with Symptomatic Hyponatremia: The SALS: A Randomized
Clinical Trial
11. Trends in Non-invasive and Invasive Mechanical Ventilation Among Medicare Beneficiaries
at the End of Life
12. Association of Therapies with Reduced Pain and Improved Quality of Life in Patients with
Fibromyalgia: A Systematic Review and Meta-analysis
13. Severe COVID-19 Infections—Knowledge Gained and Remaining Questions
14. Time to Reassess Tocilizumab’s Role in COVID-19 Pneumonia
15. Addressing the Cost of Biologic and Specialty Drugs
16. Immune Stimulation With Recombinant Human Granulocyte Colony–Stimulating Factor for
Coronavirus Disease 2019 (COVID-19)—Beware of Blind Spots
17. Non-invasive Ventilation in Seriously Ill Older Adults at the End of Life—The Evidence
Remains Elusive
18. Addressing Spiritual and Religious Needs in Advanced Illness: A Teachable Moment
19. Implications of Early Health Care Spending Reductions for Expected Spending as the
COVID-19 Pandemic Evolves
20. Risk of Severe COVID-19 Among Workers and Their Household Members
21. Diaphragm Pathology in Critically Ill Patients With COVID-19 and Post-mortem Findings
From 3 Medical Centers
22. Diversity and Representation of Physicians During the COVID-19 News Cycle
23. Outcomes of Universal COVID-19 Testing Following Detection of Incident Cases in 11 Long-
term Care Facilities
24. Association of Neighborhood Characteristics and Travel Patterns With Fatal Drug Overdoses
25. Assessment of COVID-19 Hospitalizations by Race/Ethnicity in 12 States
26. Disparities in Second-hand Smoke Exposure in the United States: National Health and
Nutrition Examination Survey 2011-2018
27. Syncope Due to Complete Heart Block—A Ticking Time Bomb
28. The Assessment of Different Diets and Mortality Fails to Address Unmeasured Confounding

29. The Assessment of Different Diets and Mortality Fails to Address Unmeasured
Confounding—Reply
30. The Uncertain Role of Corticosteroids in the Treatment of COVID-19
31. The Uncertain Role of Corticosteroids in the Treatment of COVID-19
32. The Uncertain Role of Corticosteroids in the Treatment of COVID-19—Reply
33. Inaccurate Estimates of Negotiated Reimbursement Prices for Insulin
34. Inaccurate Estimates of Negotiated Reimbursement Prices for Insulin—Reply
35. Anticoagulation Therapy and Fall Reduction
36. Complexities and Outcomes of Advance Care Planning
37. Prediction Models for COVID-19 Need Further Improvements
38. Corrections to Assessment of Variation in State Regulation of Generic Drug and
Interchangeable Biologic Substitutions
39. Coding Errors Resulting in Some US State Misclassifications
40. Error in Author Order of the Byline
41. Errors in Group Information Supplement and End Matter
42. JAMA Internal Medicine